The usefulness of periostin determination in gynecology and obstetrics

review OA: gold CC0
AI-generated summary by claude@2026-06, 2026-06-07

This review summarizes current knowledge on periostin expression in gynecology and obstetrics, highlighting its limited but emerging roles in cervical cancer, myometrial function, endometriosis, ovarian cancer, and pregnancy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07

This paper is a literature review that systematically searched PubMed and Google Scholar for English original and review articles up to December 2019 describing periostin (POSTN/OSF-2) expression in gynecology and obstetrics. The authors report that most evidence concerns POSTN in endometriosis and especially ovarian cancer, while only limited work examines uterine myometrial commitment (maintenance during pregnancy and induction of parturition) and a small number of studies assess periostin-related findings among pregnant women. They conclude that although periostin structure, signaling pathways, and functions are well described, many issues remain unresolved and further studies are needed to verify proposed hypotheses, with the caveat that the scope is limited to English-language literature and does not add new experimental data. Relevance to endometriosis: the review explicitly summarizes prior studies of periostin expression in endometriotic lesions, though its main focus is an overall synthesis of periostin knowledge across gynecology and obstetrics.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Periostin (POSTN) is a multifunctional glycoprotein that belongs to the group of extracellular matrix (ECM) proteins. Due to the molecular structure, cellular interactions, tissue locations as well functions of POSTN, we realize that its pivotal role is organization and regulation of ECM microenvironment. In available databases there is a lack of data summarizing current knowledge about POSTN expression in the field of gynecology and obstetrics. We conducted a search in PubMed of the National Library of Medicine and Google Scholar. Databases were extensively searched for all original and review articles/book chapters published in English until December 2019 and related to periostin expression. All relevant articles were reviewed and presented as appropriate. In the field of POSTN expression there is only one paper evaluating its involvement in cervical cancer cell metabolism and only two studies analyzing its myometrial commitment: maintenance during pregnancy and induction of parturition in physiology as well control of fibroids biology in pathology. Much more attention has been devoted to the expression of described protein in the endometriosis, and above all in ovarian cancer. Finally, a few studies carried out among pregnant women were presented. In this review study we presented current knowledge about periostin expression in the field of gynecology and obstetrics. Many achieved results are interesting and further studies are needed to verify some hypotheses. Structure, signaling pathways as well many functions of periostin are well-described. However, as it was clearly shown there is a lot of unknown issues which are waiting to be explored.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cell Adhesion Molecules Uterine Cervical Neoplasms Cell Adhesion Molecules Female Gynecology Gynecology Humans Neoplasm Metastasis Obstetrics Obstetrics Uterine Cervical Neoplasms

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (40)

SciLite annotations

chemicals 1
glycoprotein

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:53.586419+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK